This summary was created by AI, based on 1 opinions in the last 12 months.
According to experts, LNTH has seen solid revenue and earnings growth in the past few years, but its share price has been under pressure recently due to weak preliminary results for FY2023. The company has a strong balance sheet with minimal net debt and has been reinvesting heavily for growth. Sales are expected to grow by around 9% over the next few years. While the momentum is poor, the valuation is considered quite attractive, although there is a possibility of it being a value trap. Experts suggest waiting for growth to pick up or for the momentum to improve before considering adding this stock to the portfolio.
Lantheus is a American stock, trading under the symbol LNTH-Q on the NASDAQ (LNTH). It is usually referred to as NASDAQ:LNTH or LNTH-Q
In the last year, 1 stock analyst published opinions about LNTH-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Lantheus.
Lantheus was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Lantheus.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Lantheus published on Stockchase.
On 2024-03-28, Lantheus (LNTH-Q) stock closed at a price of $62.21.
LNTH is now trading at 9.1x times' Forward P/E. In the last few years, revenue and earnings growth were solid, but the share price has been under pressure recently after the company gave out weak preliminary result for FY2023. The balance sheet is strong, with a net debt of only $3M. The company has been reinvesting heavily in the last two years to pursue growth, along with some minor buybacks. Based on consensus estimates, sales are expected to grow by around 9% over the next few years. LNTH is a bit different from LLY and ABBV, which are drug development companies. The momentum is quite poor but we think valuation is quite attractive. It might be a value trap, and we would be less inclined to add until growth picks up or momentum improves.
Unlock Premium - Try 5i Free